Comparative Pharmacology
Head-to-head clinical analysis: NOGENIC HC versus ORTHO NOVUM 1 80 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOGENIC HC versus ORTHO NOVUM 1 80 28.
NOGENIC HC vs ORTHO-NOVUM 1/80 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NOGENIC HC contains hydrocortisone, a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription and reducing inflammation, immune responses, and cytokine production.
Combination estrogen-progestin contraceptive; primarily inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
NOGENIC HC is not a recognized drug. Please verify the name. No dosing information available.
One tablet orally once daily at the same time each day for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 80 mcg, followed by 7 placebo tablets).
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with hepatic impairment, half-life may be prolonged up to 24 hours; no dose adjustment required for renal impairment.
Norethindrone: 7-8 hours; mestranol: 10-13 hours (terminal). Steady-state achieved in 5-7 days.
Primarily hepatic metabolism; biliary excretion accounts for approximately 80%; renal elimination of inactive metabolites less than 5% as unchanged drug.
Norethindrone: 50-60% renal, 20-30% fecal; mestranol: 30-40% renal, 60-70% fecal.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive